Clinical, molecular and radiomic profile of gliomas with FGFR3-TACC3 fusions.

BACKGROUND actionable FGFR3-TACC3 (F3T3) fusions are found in approximately 3% of gliomas, but their characteristics and prognostic significance are still poorly defined. Our goal was to characterize the clinical, radiological and molecular profile of F3T3 positive diffuse gliomas. METHODS we screened F3T3 fusion by RT-PCR and FGFR3 immunohistochemistry in a large series of gliomas, characterized for the main genetic alterations, histology, and clinical evolution. We performed a radiological and radiomic case control study, using an exploratory and a validation cohort. RESULTS we screened 1,162 diffuse gliomas (951 unselected cases and 211 preselected for FGFR3 protein immunopositivity), identifying 80 F3T3 positive gliomas. F3T3 was mutually exclusive with IDH mutation (p<0.001) and EGFR amplification (p=0.01), defining a distinct molecular cluster associated with CDK4 (p=0.04) and MDM2 amplification (p=0.03). F3T3 fusion was associated with longer survival for the whole series and for glioblastomas (median OS was 31.1 versus 19.9 months, p=0.02) and was an independent predictor of better outcome on multivariate analysis.F3T3 positive gliomas had specific MRI features, affecting preferentially insula and temporal lobe, and with poorly defined tumor margins. F3T3 fusion was correctly predicted by radiomics analysis on both the exploratory (AUC=0.87) and the validation MRI (AUC=0.75) cohort. Using Cox proportional hazards models, radiomics predicted survival with a high C-Index (0.75, SD 0.04), while the model combining clinical, genetic and radiomic data showed the highest C-index (0.81, SD 0.04). CONCLUSION F3T3 positive gliomas have distinct molecular and radiological features, and better outcome.

[1]  A. Iavarone,et al.  Diffuse gliomas with FGFR3‐TACC3 fusion have characteristic histopathological and molecular features , 2018, Brain pathology.

[2]  K. Hoang-Xuan,et al.  FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas , 2018, Neurology.

[3]  Tala,et al.  A metabolic function of FGFR3-TACC3 gene fusions in cancer , 2017, Nature.

[4]  Brian Avants,et al.  Improved accuracy of lesion to symptom mapping with multivariate sparse canonical correlations , 2017, Neuropsychologia.

[5]  V. Calvo,et al.  PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy , 2017, Scientific Reports.

[6]  Andriy Fedorov,et al.  Computational Radiomics System to Decode the Radiographic Phenotype. , 2017, Cancer research.

[7]  C. Duyckaerts,et al.  Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co‐deleted anaplastic gliomas , 2017, Brain pathology.

[8]  E. Nanba,et al.  Epileptic phenotype of FGFR3-related bilateral medial temporal lobe dysgenesis , 2017, Brain and Development.

[9]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[10]  Mauricio Reyes,et al.  Fully automatic GBM segmentation in the TCGA-GBM dataset: Prognosis and correlation with VASARI features , 2015, Scientific Reports.

[11]  Egon L. Willighagen,et al.  RRegrs: an R package for computer-aided model selection with multiple regression models , 2015, Journal of Cheminformatics.

[12]  Emily Berry,et al.  FGFR3–TACC3: A novel gene fusion in cervical cancer , 2015, Gynecologic oncology reports.

[13]  A. Iavarone,et al.  Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma , 2015, Clinical Cancer Research.

[14]  Y. Marie,et al.  Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes , 2014, Neurology.

[15]  Zhi‐hua Liu,et al.  Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma , 2014, Cancer biology & therapy.

[16]  K. Hoang-Xuan,et al.  TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations , 2014, British Journal of Cancer.

[17]  P. Jänne,et al.  Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma , 2014, Clinical Cancer Research.

[18]  Y. Marie,et al.  Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes , 2014, Neurology.

[19]  C. Crainiceanu,et al.  Statistical normalization techniques for magnetic resonance imaging , 2014, NeuroImage: Clinical.

[20]  S. Plevritis,et al.  Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. , 2014, Radiology.

[21]  A. Righini,et al.  Does the co-occurrence of FGFR3 gene mutation in hypochondroplasia, medial temporal lobe dysgenesis, and focal epilepsy suggest a syndrome? , 2014, Pediatric neurology.

[22]  Benjamin M. Ellingson,et al.  Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics , 2014, Current Neurology and Neuroscience Reports.

[23]  T. Cloughesy,et al.  Probabilistic Radiographic Atlas of Glioblastoma Phenotypes , 2013, American Journal of Neuroradiology.

[24]  Liu Wei,et al.  LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. , 2013, Cancer cell.

[25]  M. Knowles,et al.  Oncogenic FGFR3 gene fusions in bladder cancer , 2012, Human molecular genetics.

[26]  D. Brat,et al.  Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.

[27]  M. Sanson,et al.  Comparative assessment of 5 methods (methylation‐specific polymerase chain reaction, methylight, pyrosequencing, methylation‐sensitive high‐resolution melting, and immunohistochemistry) to analyze O6‐methylguanine‐DNA‐methyltranferase in a series of 100 glioblastoma patients , 2012, Cancer.

[28]  Arno Klein,et al.  A reproducible evaluation of ANTs similarity metric performance in brain image registration , 2011, NeuroImage.

[29]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[30]  T. Horvath,et al.  Fgfr2 Is Required for the Development of the Medial Prefrontal Cortex and Its Connections with Limbic Circuits , 2010, The Journal of Neuroscience.

[31]  K. Hoang-Xuan,et al.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Hoang-Xuan,et al.  Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma , 2009, Neuropathology and applied neurobiology.

[33]  K. Aldape,et al.  Identification of noninvasive imaging surrogates for brain tumor gene-expression modules , 2008, Proceedings of the National Academy of Sciences.

[34]  Guido Gerig,et al.  User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability , 2006, NeuroImage.

[35]  N. Šestan,et al.  Midline radial glia translocation and corpus callosum formation require FGF signaling , 2006, Nature Neuroscience.

[36]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[37]  J. Cooper,et al.  FGFR3 regulates brain size by controlling progenitor cell proliferation and apoptosis during embryonic development. , 2005, Developmental biology.

[38]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[39]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .